About Us
Overview
Powering better medical research using state-of-the-art platform technologies
Human 3D bioprinted platforms for translational drug discovery
Immunoglobulin Y (IgY)-based diagnostics and for use as prophylactic and therapeutic agents
Reagene Biosciences
Commercialisation of technologies and platforms
Reagene Innovations
Wholly owned subsidiary of Reagene Biosciences
Focused on developing technologies, product concepts and products through POC
Who we are
Reagene Biosciences (Bangalore, incorporated 2016) and Reagene Innovations (Hyderabad, incorporated 2018) are innovative platform technology companies.
Reagene Biosciences is developing ImmunIgY class of products in collaboration with ProdigY Biotech (USA) (www.prodigybiotech.com) and Kyntox Biotech (Bangalore, India) . The first product for COVID has been globally launched through Lay Sciences Inc (USA) (www.laysciences.com).
Reagene Innovations is involved in developing translational technology platforms such as 3D bio-printing as alternatives to animal models to bridge the gap between preclinical and clinical translation. Using this innovative platform Reagene Innovations developed a human vascular lung model which was utilized to identify repurposed drug molecules to mitigate COVID-19 disease (https://www.biorxiv.org/content/10.1101/2021.10.19.464951v1).
Giving back to biosciences
We are a team of scientists who have seen the trials and tribulations of discovery research across large pharma and biotech companies globally and are striving to give back to the industry. Our team has over 100 years of combined experience in:
Drug discovery and regulatory development
Nutraceutical development
Bio-therapeutics for rare and orphan diseases
Medical devices
3d bio-printed tools supporting alternatives to animal models
IgY antibody development and characterisation
Diagnostics
Reagents
Consulting services
A new order
At Reagene, we strongly believe that there now exists sufficient technology know-how to overturn some of the commonly followed practices/ dogma and instead establish a new order for discovery research.